GLP-1R agonists are widely used in the management of type 2 diabetes due to their ability to enhance insulin secretion in a glucose-dependent manner. They help lower blood sugar levels by stimulating the release of insulin from pancreatic beta cells while simultaneously suppressing the secretion of glucagon, a hormone that raises blood glucose. Beyond glycemic control, these agonists are also effective in promoting weight loss, making them a valuable option for patients with obesity or overweight conditions. Additionally, they have shown cardiovascular benefits, reducing the risk of major adverse cardiovascular events in high-risk patients. GLP-1R agonists are administered via subcutaneous injection and are often prescribed as part of a comprehensive treatment plan that includes lifestyle modifications and other medications. Their ability to address multiple aspects of metabolic health has made them a cornerstone in diabetes care.